{"id":"W1521559493","doi":"10.1002/cncr.29227","title":"A phase II trial of second‐line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma","year":2015,"lang":"en","type":"article","venue":"Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Axitinib; Medicine; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Progressive disease; Hepatocellular carcinoma; Internal medicine; Adverse effect; Gastroenterology; Oncology; Sorafenib; Urology; Clinical trial; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003155656,0.0002408949,0.0006503202,0.0001903165,0.00004498192,0.000007601956,0.0001049538,0.00013226,0.0003517223],"category_scores_gemma":[0.00005062623,0.0002069917,0.0003928903,0.0004021552,0.00004400105,0.0001071646,0.00003555429,0.0001401617,0.00000921492],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001622843,"about_ca_system_score_gemma":0.0005402433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001541034,"about_ca_topic_score_gemma":0.00004397055,"domain_scores_codex":[0.9984252,0.00007208093,0.0004833048,0.0003561073,0.0003106707,0.000352603],"domain_scores_gemma":[0.9991204,0.00003430593,0.0001408996,0.0003592371,0.0001108791,0.0002342776],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0502042,0.003601218,0.7875677,0.0001029796,0.0004138682,0.0008810642,0.002632711,0.000001860122,0.06452745,0.00001775356,0.0003718211,0.0896774],"study_design_scores_gemma":[0.6375774,0.02171198,0.004274053,0.0002999881,0.0004066904,0.00001964827,0.0003094403,0.002549347,0.3138886,0.00007533278,0.01836717,0.0005203662],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9812112,0.01565512,0.00001310796,0.000276927,0.0004785916,0.001763312,0.00003483993,0.00004075555,0.0005261302],"genre_scores_gemma":[0.9979488,0.0002072882,0.0002820509,0.0001519871,0.0002897086,0.0003378649,0.00007431534,0.00004617591,0.0006617897],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7832936,"threshold_uncertainty_score":0.8440875,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1064780361000544,"score_gpt":0.3306505208578445,"score_spread":0.2241724847577901,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}